e-learning
resources
Vienna 2012
Monday, 03.09.2012
Scores, biomarkers and risk factors in respiratory infections
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Comparision of procalcitonin and CURB-65 in pneumonia
S. Ozsu, I. Yilmaz, Y. Abul, F. Öztuna, Y. Bulbul, T. Ozlu (Trabzon, Turkey)
Source:
Annual Congress 2012 - Scores, biomarkers and risk factors in respiratory infections
Session:
Scores, biomarkers and risk factors in respiratory infections
Session type:
Thematic Poster Session
Number:
2510
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Ozsu, I. Yilmaz, Y. Abul, F. Öztuna, Y. Bulbul, T. Ozlu (Trabzon, Turkey). Comparision of procalcitonin and CURB-65 in pneumonia. Eur Respir J 2012; 40: Suppl. 56, 2510
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Prognostic value of procalcitonin in community-acquired pneumonia
Source: Eur Respir J 2011; 37: 384
Year: 2011
Predictive value of procalcitonin in ventilator-associated pneumonia
Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Year: 2007
Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia
Source: Eur Respir J 2008; 31: 356-362
Year: 2008
Usefulness of C-reactive protein and procalcitonin in predicting mortality in community-acquired pneumonia
Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Year: 2008
Correlation of procalcitonin and CRP in community-acquired pneumonia with CRB-65 score and prognosis – results from the German competence network CAPNETZ
Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia
Year: 2006
Serum procalcitonin and community-acquired pneumonia in childhood
Source: Eur Respir J 2005; 26: Suppl. 49, 167s
Year: 2005
D-dimer elevation is associated with severity of community-acquired pneumonia according to CURB-65 and PSI
Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia
Year: 2006
Comparison of biomarkers and SOFA score prognostic value in ventilator-associated pneumonia
Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia
Year: 2009
C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia
Source: Eur Respir J 2010; 35: 805-811
Year: 2010
Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP)
Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Year: 2007
Role of procalcitonin in predicting severity and in-hospital mortality in patients with community-acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues
Year: 2016
Serum procalcitonin and C-reactive protein in children with community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 488s
Year: 2006
Procalcitonin has wider applicability in community-acquired pneumonia than other biomarkers
Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection
Year: 2018
Admission CRP and D-dimer levels can identify high-risk patients with community-acquired pneumonia
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010
C-reactive protein in community-acquired pneumonia
Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia
Year: 2006
Predicting severe sepsis in community-acquired pneumonia using CURB65 and PSI scores
Source: Annual Congress 2008 - Diagnostic tests in lower respiratory tract infections
Year: 2008
Diagnostic and prognostic utility of procalcitonin (PCT) measurements in patients with hospitalized community-acquired pneumonia (CAP)
Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers
Year: 2009
Can procalcitonin or C-reactive protein predict supporative lung complications and ARDS at severe community-acquired pneumonia (CAP)?
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
CUR-65 score for community-acquired pneumonia predicted mortality better than CURB-65 score in low-mortality-rate settings
Source: International Congress 2015 – CAP: prognostic factors in frail patients
Year: 2015
Performance of CURB-65 and CURB-age in community acquired pneumonia (CAP)
Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept